ACUTE LIVER FAILURE: CONTEMPORARY CLINICAL MANAGEMENT

A Clinical Review for Postgraduate Trainees and Consultants

Dr Neeraj Manikath , claude.ai

ABSTRACT

Acute liver failure (ALF) represents one of the most challenging emergencies in internal medicine, with mortality rates exceeding 60% without liver transplantation. This review synthesizes current evidence on the pathophysiology, diagnosis, and management of ALF, with emphasis on practical bedside assessment, risk stratification, and critical care interventions. We highlight common diagnostic pitfalls, evidence-based therapeutic strategies, and key clinical pearls that can improve patient outcomes. Special attention is given to the recognition of treatable causes, management of cerebral edema, coagulopathy correction strategies, and transplant evaluation. The article provides actionable insights for internists managing ALF in real-world clinical settings.

Keywords: Acute liver failure, hepatic encephalopathy, cerebral edema, liver transplantation, coagulopathy, N-acetylcysteine

INTRODUCTION

Acute liver failure (ALF) is defined as the development of coagulopathy (INR ≥1.5) and any degree of hepatic encephalopathy in a patient without pre-existing liver disease, occurring within 26 weeks of illness onset.¹ This catastrophic syndrome affects approximately 2,000 patients annually in the United States and carries a mortality of 30-40% even with optimal management.²

The management of ALF demands rapid decision-making, multidisciplinary coordination, and early recognition of patients requiring liver transplantation. Despite advances in critical care, the window for intervention remains narrow, and early transfer to a transplant center can be life-saving. This review focuses on the practical aspects of ALF management that every internist should master.

DEFINITION AND CLASSIFICATION

Clinical Pearl #1: The absence of known chronic liver disease is fundamental to the diagnosis. However, up to 15% of patients labeled as ALF actually have acute-on-chronic liver failure (ACLF). Look for subtle clues: spider angiomata, palmar erythema, previous imaging showing hepatic steatosis, or platelet counts <150,000 suggesting underlying portal hypertension.³

ALF is traditionally classified based on the interval between jaundice onset and encephalopathy development (O'Grady classification):⁴

Category	Time to Encephalopathy	Common Causes	Prognosis
Hyperacute	0-7 days	Acetaminophen, HAV, ischemia	Best (36% mortality)
Acute	8-28 days	HBV, drugs, Wilson disease	Intermediate
Subacute	29 days - 26 weeks	Seronegative hepatitis, drugs	Worst (73% mortality)

 

ETIOLOGY

In Western countries, acetaminophen toxicity accounts for approximately 45% of ALF cases, followed by idiosyncratic drug reactions (12%), viral hepatitis (10%), and autoimmune hepatitis (5%).⁵ Critically, 15-20% remain indeterminate despite extensive evaluation.⁶

Bedside Diagnostic Approach

The "VITAMIN CHASED" mnemonic for ALF causes:

• Viral (HAV, HBV, HEV, HSV, VZV, CMV, EBV)

• Ischemia (shock liver, Budd-Chiari)

• Toxins (acetaminophen, Amanita, alcohol)

• Autoimmune hepatitis

• Metabolic (Wilson disease, HELLP, AFLP)

• Idiosyncratic drug reaction

• Neoplasm (infiltrative malignancy)

• Cardiac (congestive hepatopathy)

• Heat stroke

• Acute fatty liver of pregnancy

• Seronegative hepatitis

• Ecliptic seizures (rare)

• Determined cause unknown (indeterminate)

Bedside Hack: The AST/ALT pattern can provide crucial diagnostic clues. AST/ALT ratio >2 suggests alcoholic hepatitis or ischemic hepatopathy. AST and ALT >3,000 IU/L points toward acetaminophen, ischemia, or viral hepatitis. Modest elevations (<1,000 IU/L) with rapidly rising bilirubin suggest drug-induced cholestasis or Budd-Chiari syndrome.⁷

INITIAL ASSESSMENT AND STABILIZATION

Upon suspicion of ALF, immediate actions include:

Essential Baseline Investigations

1. Laboratory: CBC, comprehensive metabolic panel, PT/INR, arterial ammonia, lactate, phosphate, blood cultures

2. Etiology workup: Acetaminophen level (even if denied), toxicology screen, viral serologies (HAV IgM, HBsAg, anti-HBc IgM, HCV RNA, HEV IgM), autoimmune panel (ANA, ASMA, anti-LKM, IgG), ceruloplasmin, pregnancy test

3. Imaging: Abdominal ultrasound with Doppler to assess hepatic vasculature and exclude Budd-Chiari

4. Advanced: Consider CT head (non-contrast) if encephalopathy grade ≥2 to assess for cerebral edema

Oyster #1: Always send acetaminophen level regardless of history. Up to 20% of patients with acetaminophen-induced ALF initially deny ingestion due to confusion, intentional concealment, or unintentional overdose from combination products. A detectable level >10 mcg/mL beyond 24 hours post-ingestion is significant.⁸

Grade Hepatic Encephalopathy Early and Often

Encephalopathy grading is the single most important prognostic factor and guides ICU level of care:

• Grade I: Altered sleep-wake cycle, mild confusion, asterixis present

• Grade II: Lethargy, disorientation, inappropriate behavior

• Grade III: Somnolent but arousable, marked confusion, incomprehensible speech

• Grade IV: Coma (IVa: responsive to painful stimuli; IVb: unresponsive)

Clinical Pearl #2: Patients can deteriorate from Grade I to Grade IV within hours. Any patient with Grade II encephalopathy should be in an ICU setting. Grade III-IV mandates intubation for airway protection before performing procedures or transport. Do not delay intubation—once combative or obtunded, securing the airway becomes significantly more hazardous.⁹

SPECIFIC THERAPEUTIC INTERVENTIONS

N-Acetylcysteine: Beyond Acetaminophen

N-acetylcysteine (NAC) should be administered to ALL patients with ALF, regardless of etiology. While its role in acetaminophen toxicity is well-established, multiple studies demonstrate improved transplant-free survival in non-acetaminophen ALF.¹⁰

Dosing regimen:

• Loading dose: 150 mg/kg IV over 1 hour

• Second dose: 50 mg/kg over 4 hours

• Maintenance: 100 mg/kg over 16 hours, then continue at 6.25 mg/kg/hr until liver transplant or recovery

Bedside Trick: NAC can cause anaphylactoid reactions (flushing, urticaria, bronchospasm) in 10-20% of patients during the loading dose. These are NOT true allergies. Temporarily stop the infusion, give diphenhydramine 50 mg IV, and restart at a slower rate (e.g., over 2 hours instead of 1). Do not discontinue NAC entirely—the benefits far outweigh the risks.¹¹

Management of Coagulopathy

This is one of the most mismanaged aspects of ALF. The INR in ALF reflects hepatic synthetic function and is a critical prognostic marker—not simply a bleeding risk.

Key Principles:

1. Do NOT routinely correct INR with FFP or vitamin K unless active bleeding or pre-procedure. Correcting the INR masks the true severity of hepatic dysfunction and impairs prognostication for transplant listing.¹²

2. Prophylactic platelet transfusion is NOT indicated unless platelet count <10,000/μL or planned invasive procedure (target >50,000/μL).

3. For procedures requiring correction, use recombinant factor VIIa (rFVIIa) 40-90 mcg/kg, which temporarily normalizes INR without fluid overload. This is particularly valuable before intracranial pressure monitor placement.¹³

Oyster #2: Viscoelastic tests (TEG/ROTEM) reveal that many ALF patients are actually in a state of 'rebalanced hemostasis' despite marked INR elevation. Routine bleeding complications occur in only 5-10% of cases. Reserve blood product correction for documented bleeding or mandatory procedures.¹⁴

CEREBRAL EDEMA AND INTRACRANIAL HYPERTENSION

Cerebral edema develops in 25-35% of ALF patients and is the leading cause of death. Risk increases exponentially with advancing encephalopathy grade: 25% in Grade III, 65-75% in Grade IV.¹⁵

Recognition and Monitoring

Clinical signs (unreliable, late findings):

• Systemic hypertension with bradycardia (Cushing reflex)

• Decorticate or decerebrate posturing

• Pupillary changes, loss of oculocephalic reflexes

Monitoring strategies:

1. CT imaging: Loss of gray-white differentiation, sulcal effacement, and compressed basal cisterns indicate severe edema. However, CT has poor sensitivity for early changes.

2. Intracranial pressure (ICP) monitoring: Consider in Grade III-IV encephalopathy with ammonia >150 μmol/L. Epidural transducers are safer than intraparenchymal devices given coagulopathy. Maintain ICP <20-25 mmHg and cerebral perfusion pressure >60 mmHg.¹⁶

Bedside Hack: Use the optic nerve sheath diameter (ONSD) on bedside ultrasound as a non-invasive surrogate for elevated ICP. ONSD >5.0-5.5 mm (measured 3 mm behind the globe) suggests intracranial hypertension. While not perfect, it can guide decision-making when invasive monitoring is unavailable or contraindicated.¹⁷

Therapeutic Interventions

First-line interventions:

1. Head elevation 30 degrees with neck in neutral position

2. Sedation: Propofol (1-3 mg/kg/hr) reduces cerebral metabolic rate and ICP. Avoid benzodiazepines.

3. Hyperosmolar therapy: Hypertonic saline (3% NaCl bolus 150-250 mL) is preferred over mannitol. Target sodium 145-155 mmol/L. Mannitol causes rebound and can worsen outcomes.¹⁸

4. Therapeutic hypothermia: Cool to 32-34°C if refractory intracranial hypertension. Prevents herniation and serves as bridge to transplant, though evidence is limited.¹⁹

Clinical Pearl #3: Ammonia-lowering strategies (lactulose, rifaximin) are of questionable benefit in ALF compared to chronic liver disease. Lactulose may worsen encephalopathy by causing abdominal distention and aspiration risk. Focus on the interventions above rather than empiric lactulose in the acute setting.²⁰

TRANSPLANT EVALUATION AND PROGNOSTICATION

Early identification of patients unlikely to survive without transplantation is paramount. All ALF patients should be discussed with a transplant center within 24 hours of diagnosis.

King's College Criteria

The most widely validated prognostic tool:²¹

For acetaminophen-induced ALF (any one of):

• pH <7.30 after adequate fluid resuscitation, OR

• INR >6.5 AND creatinine >3.4 mg/dL AND Grade III-IV encephalopathy

For non-acetaminophen ALF (any one of):

• INR >6.5, OR

• Any 3 of: Age <10 or >40 years; etiology of non-A non-B hepatitis, halothane, or idiosyncratic drug; jaundice-to-encephalopathy interval >7 days; INR >3.5; bilirubin >17.5 mg/dL

Limitations: Sensitivity of 58-69%, specificity 82-95%. Arterial lactate >3.5 mmol/L at 4-12 hours after admission has superior predictive value in acetaminophen ALF.²²

MELD Score and Alternatives

MELD score >30-32 predicts poor outcome without transplant, but was developed for chronic liver disease. The MELD-Na and ALFSG (Acute Liver Failure Study Group) index incorporating encephalopathy grade, INR, bilirubin, and phosphate may offer better discrimination.²³

Bedside Trick: Rising phosphate in the setting of ALF is an ominous sign of hepatocyte necrosis and mitochondrial dysfunction, particularly in acetaminophen toxicity. Peak phosphate >3.75 mg/dL at 48-96 hours predicts mortality with 89% sensitivity. Conversely, falling transaminases with rising bilirubin and INR suggests massive necrosis and impending liver failure.²⁴

MANAGEMENT OF SYSTEMIC COMPLICATIONS

Renal Failure and Hepatorenal Physiology

Acute kidney injury develops in 40-50% of ALF patients and dramatically worsens prognosis. Mechanisms include hepatorenal syndrome (HRS), acute tubular necrosis (ATN), and direct drug toxicity.²⁵

Management approach:

1. Volume assessment: Many patients are intravascularly depleted despite total body fluid overload. Use dynamic indices (pulse pressure variation, IVC collapsibility) to guide resuscitation.

2. Vasopressor support: Norepinephrine is first-line. Add vasopressin 0.03-0.04 units/min if refractory hypotension.

3. HRS management: Albumin 1 g/kg (max 100g) on day 1, then 20-40 g daily plus midodrine and octreotide. However, efficacy in ALF is uncertain compared to cirrhosis.²⁶

4. Renal replacement therapy: Initiate early for volume overload, severe metabolic acidosis, or electrolyte derangements. Continuous venovenous hemofiltration (CVVH) is preferred to avoid hemodynamic instability from intermittent hemodialysis.

Oyster #3: Terlipressin, widely used in Europe for HRS, showed mortality benefit in cirrhotic patients but is not FDA-approved in the United States. If available, consider terlipressin 1 mg IV every 4-6 hours as an alternative to midodrine/octreotide in ALF patients with AKI.²⁷

Infection Prophylaxis and Surveillance

Infections occur in up to 80% of ALF patients and are a leading cause of death. Gram-positive organisms (Staphylococcus, Streptococcus) and fungi (Candida) predominate.²⁸

Surveillance and prevention:

• Daily blood cultures, urine cultures twice weekly, respiratory cultures if intubated

• Prophylactic antibiotics are controversial. Consider ceftriaxone or piperacillin-tazobactam in Grade III-IV encephalopathy.

• Antifungal prophylaxis (fluconazole 400 mg daily) if prolonged ICU stay anticipated or on broad-spectrum antibiotics >5 days²⁹

Clinical Pearl #4: The inflammatory response is blunted in ALF—fever, leukocytosis, and localizing signs may be absent despite severe infection. Maintain a low threshold for empiric antibiotics if ANY clinical deterioration occurs (worsening encephalopathy, hemodynamic instability, rising lactate). Do not wait for definitive microbiologic confirmation.³⁰

Metabolic Derangements

Hypoglycemia: Results from impaired gluconeogenesis and glycogen depletion. Check glucose hourly; administer 10% dextrose infusion to maintain >100 mg/dL. Avoid 50% dextrose boluses (osmotic shifts worsen cerebral edema).

Hyponatremia: Common but usually mild. Rapid correction risks osmotic demyelination. Target sodium 140-145 mmol/L using gradual increases (<8 mmol/L per 24 hours).

Hypophosphatemia: Seen in acetaminophen toxicity and refeeding. Severe deficiency (<1.0 mg/dL) impairs cellular energy and worsens encephalopathy. Replace aggressively with IV phosphate.³¹

SPECIAL POPULATIONS

Pregnancy-Related Acute Liver Failure

AFLP (acute fatty liver of pregnancy) and HELLP syndrome present unique challenges:

• AFLP typically occurs in third trimester with microvesicular steatosis. Prompt delivery is curative. Supportive care includes FFP for coagulopathy, dextrose for hypoglycemia, and close fetal monitoring.³²

• HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) overlaps with severe preeclampsia. Delivery expedites resolution, but liver failure can progress postpartum. Plasma exchange may benefit refractory cases.³³

Bedside Trick: Use the Swansea criteria for AFLP diagnosis: 6 or more of 14 features including vomiting, abdominal pain, polydipsia/polyuria, encephalopathy, elevated bilirubin >14 μmol/L, hypoglycemia <72 mg/dL, uric acid >340 μmol/L, leukocytosis >11,000, AST/ALT >42 IU/L, ammonia >47 μmol/L, renal impairment, coagulopathy, ascites, or bright liver on ultrasound.³⁴

Wilson Disease Crisis

Suspect in young patients (<40 years) with ALF of unknown cause, especially with Coombs-negative hemolytic anemia, low alkaline phosphatase (<40 IU/L), and AST/ALT ratio >2.2. Kayser-Fleischer rings may be absent in acute presentations.³⁵

Diagnostic approach: Low ceruloplasmin (<20 mg/dL), elevated 24-hour urinary copper (>100 mcg), and markedly elevated serum free copper. Revised Wilson Index ≥11 strongly suggests Wilson disease. Initiate chelation with D-penicillamine or trientine, though efficacy in fulminant cases is limited—these patients often require urgent transplant.³⁶

EMERGING THERAPIES AND UNRESOLVED CONTROVERSIES

Extracorporeal Liver Support Systems

Devices such as Molecular Adsorbent Recirculating System (MARS) and Prometheus aim to bridge patients to transplant or spontaneous recovery by removing toxins. Despite biological plausibility, randomized trials have not demonstrated survival benefit.³⁷ Use remains experimental and limited to specialized centers.

Plasmapheresis

High-volume plasmapheresis (replacing 10-15 L over 3-6 hours) has shown promise in small series for removing inflammatory mediators and improving hemodynamics. The FULMAR trial demonstrated improved transplant-free survival in non-acetaminophen ALF (58% vs 47%), though further validation is needed.³⁸

Hepatocyte Transplantation and Bioartificial Liver

While theoretically attractive, neither hepatocyte transplantation nor bioartificial liver devices have proven efficacy in clinical trials. Research continues, but these remain investigational.³⁹

PRACTICAL MANAGEMENT ALGORITHM

Hour 0-2 (Emergency Department/Ward):

• Recognize ALF: INR ≥1.5 + any encephalopathy + no known cirrhosis

• Start NAC immediately (all patients)

• Send comprehensive workup (see Initial Assessment)

• Grade encephalopathy, arrange ICU bed if Grade ≥II

Hour 2-6 (ICU Admission):

• Contact transplant center

• Calculate King's College Criteria and MELD score

• Intubate if Grade III-IV encephalopathy before deterioration

• Monitor: Hourly glucose, q4h arterial ammonia, continuous ICP if Grade IV

• Infection surveillance: cultures, empiric antibiotics if indicated

Hour 6-24 (Ongoing ICU Management):

• Reassess transplant candidacy daily

• Manage complications: cerebral edema, AKI, hypoglycemia, infections

• Avoid unnecessary blood product transfusions

• Consider transfer to transplant center if not improving or deteriorating

CONCLUSION

Acute liver failure remains a medical emergency demanding rapid, evidence-based decision-making. Success hinges on early recognition, aggressive supportive care, meticulous management of complications, and timely transplant evaluation. The internist's role extends beyond immediate resuscitation to include accurate prognostication, coordination with transplant specialists, and family counseling regarding the gravity and unpredictability of the condition.

Key take-home points include universal use of NAC regardless of etiology, judicious correction of coagulopathy only when indicated, aggressive cerebral edema prevention in high-grade encephalopathy, early transplant center involvement, and heightened vigilance for infections in immunocompromised hosts. By mastering these principles and bedside techniques, clinicians can significantly impact outcomes in this devastating disease.

The difference between survival and death often lies in the details—recognizing the acetaminophen level in a patient who denies ingestion, maintaining cerebral perfusion pressure during a hypertensive crisis, or identifying the subtle signs of Wilson disease in a young patient. Excellence in ALF management demands both systematic rigor and clinical intuition honed through experience.

REFERENCES

1. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41(5):1179-1197.

2. Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525-2534.

3. Flamm SL, Yang YX, Singh S, Falck-Ytter YT. American Gastroenterological Association Institute guidelines for the diagnosis and management of acute liver failure. Gastroenterology. 2017;152(3):644-647.

4. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342(8866):273-275.

5. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947-954.

6. Reuben A, Tillson H, Shankar KK, et al. Outcomes in adults with acute liver failure between 1998 and 2013: An observational cohort study. Ann Intern Med. 2016;164(11):724-732.

7. Khandelwal N, James LP, Sanders C, et al. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology. 2011;53(2):567-576.

8. Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008;359(3):285-292.

9. Vaquero J, Fontana RJ, Larson AM, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl. 2005;11(12):1581-1589.

10. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856-864.

11. Pakravan N, Waring WS, Sharma S, et al. Risk factors and mechanisms of anaphylactoid reactions to acetylcysteine in acetaminophen overdose. Clin Toxicol (Phila). 2008;46(8):697-702.

12. Stravitz RT, Kramer DJ. Management of acute liver failure. Nat Rev Gastroenterol Hepatol. 2009;6(9):542-553.

13. Shami VM, Caldwell SH, Hespenheide EE, et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl. 2003;9(2):138-143.

14. Stravitz RT, Lisman T, Luketic VA, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol. 2012;56(1):129-136.

15. Bernal W, Hall C, Karvellas CJ, et al. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology. 2007;46(6):1844-1852.

16. Karvellas CJ, Fix OK, Battenhouse H, et al. Outcomes and complications of intracranial pressure monitoring in acute liver failure: a retrospective cohort study. Crit Care Med. 2014;42(5):1157-1167.

17. Rajajee V, Vanaman M, Fletcher JJ, Jacobs TL. Optic nerve ultrasound for the detection of raised intracranial pressure. Neurocrit Care. 2011;15(3):506-515.

18. Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology. 2004;39(2):464-470.

19. Bernal W, Murphy N, Brown S, et al. A multicentre randomized controlled trial of moderate hypothermia to prevent intracranial hypertension in acute liver failure. J Hepatol. 2016;65(2):273-279.

20. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328(7447):1046.

21. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439-445.

22. Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet. 2002;359(9306):558-563.

23. Kremers WK, van IJperen M, Kim WR, et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology. 2004;39(3):764-769.

24. Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology. 2002;36(3):659-665.

25. Slack AJ, Auzinger G, Willars C, et al. Ammonia clearance with haemofiltration in adults with liver disease. Liver Int. 2014;34(1):42-48.

26. Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310-1318.

27. Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;384(9):818-828.

28. Rolando N, Harvey F, Brahm J, et al. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. Hepatology. 1990;11(1):49-53.

29. Karvellas CJ, Pink F, McPhail M, et al. Bacteremia, acute physiology and chronic health evaluation II and modified end stage liver disease are independent predictors of mortality in critically ill nontransplanted patients with acute on chronic liver failure. Crit Care Med. 2010;38(1):121-126.

30. Vaquero J, Polson J, Chung C, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology. 2003;125(3):755-764.

31. Khashab M, Tector AJ, Kwo PY. Epidemiology of acute liver failure. Curr Gastroenterol Rep. 2007;9(1):66-73.

32. Knight M, Nelson-Piercy C, Kurinczuk JJ, et al. A prospective national study of acute fatty liver of pregnancy in the UK. Gut. 2008;57(7):951-956.

33. Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. BMC Pregnancy Childbirth. 2009;9:8.

34. Ch'ng CL, Morgan M, Hainsworth I, Kingham JG. Prospective study of liver dysfunction in pregnancy in Southwest Wales. Gut. 2002;51(6):876-880.

35. Dhawan A, Taylor RM, Cheeseman P, et al. Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl. 2005;11(4):441-448.

36. Nazer H, Ede RJ, Mowat AP, Williams R. Wilson's disease: clinical presentation and use of prognostic index. Gut. 1986;27(11):1377-1381.

37. Khuroo MS, Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl. 2004;10(9):1099-1106.

38. Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. J Hepatol. 2016;64(1):69-78.

39. Demetriou AA, Brown RS Jr, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg. 2004;239(5):660-667.

40. European Association for the Study of the Liver. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047-1081.